ID | 115284 |
Author |
Bando, Hiroshi
Tokushima University|Japan Low Carbohydrate Diet Promotion Association
KAKEN Search Researchers
|
Keywords | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
Phlorizin
Antihypertensive Agents (AHA)
Cardiovascular Event
Blood Pressure
|
Content Type |
Journal Article
|
Description | Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) has been in focus for the pharmacotherapy of diabetes. SGLT2i contributes to decreasing blood pressure (BP) to some degree. BP changes were analyzed in 4 well-known mega-studies. They are Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study, Canagliflozin cardioVascular Assessment Study (CANVAS), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) and Dapagliflozin Effect on CardiovascuLAR Events (DECLARE)-TIMI 58. The ultimate goal of antihypertensive and hypoglycemic agents is not the achievement of target values, but the suppression of cardiovascular events. SGLT-2i show excellent strategy for event suppression and adjunct method for hypertension.
|
Journal Title |
Asploro Journal of Biomedical and Clinical Case Reports
|
ISSN | 25820370
|
Publisher | Asploro
|
Volume | 3
|
Issue | 3
|
Start Page | 186
|
End Page | 190
|
Published Date | 2020-08-28
|
Rights | © 2020 Bando H. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
|
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
Medical Sciences
|